MindMed has dosed the first subject in a Phase III study of MM120 tablets for the treatment of generalised anxiety disorder.

Mind Medicine Inc., a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health ...

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...

PHOENIXVILLE, PA — Facet Life Sciences has been selected as the U.S. regulatory partner for Cybin Inc., a neuropsychiatry ...

Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...

(NASDAQ: MNMD), a biopharmaceutical company in the clinical stage with a market capitalization of $548.52 million, announced today that its experimental treatment for Generalized Anxiety Disorder ...

Their descriptions of narcissistic personality disorder were often so exaggerated and unrealistic that they made narcissists sound as if they were either comic book villains or superheroes.

While people with Generalized Anxiety Disorder (GAD) are more prone to high-functioning anxiety, the latter is not a diagnosed mental health disorder. It is, instead, a catch-all term – however ...

A new guideline published today recommends chronic asthma should be diagnosed by healthcare professionals when people first show symptoms by using simple tests. The guideline also says healthcare ...

Post-traumatic stress disorder (PTSD) can happen after a person experiences a traumatic event that causes them to feel scared, shocked, or helpless. It can have long-term effects, including ...

FASB published a proposed Accounting Standards Update (ASU) that would establish authoritative guidance on the accounting for government grants received by business entities, guidance that would serve ...